Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Mesoblast and FDA agree on adult stem cell trial in type 2 diabetes

Nov. 24, 2011

Takeda files NDA for fixed-dose tablet of alogliptin/metformin

Nov. 24, 2011

Takeda Pharmaceuticals reports novel acetyl-CoA carboxylase inhibitors

Nov. 24, 2011

New compounds for bone disorders prepared by Daiichi Sankyo

Nov. 24, 2011

FDA accepts for review Regeneron's sBLA for Arcalyst

Nov. 23, 2011

Trimel Pharmaceuticals provides update on CompleoTRT study

Nov. 23, 2011

Phase III study of DiaPep277 in type 1 diabetes meets primary endpoint

Nov. 23, 2011

Merck & Co. presents novel lysosomal Pro-X carboxypeptidase inhibitors

Nov. 22, 2011

FDA pushes back review date for Takeda's type 2 diabetes therapies

Nov. 21, 2011

GSK reports topline results from first of eight phase III studies of albiglutide in type 2 diabetes

Nov. 21, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...